Clinical Trials 2017-06-23T16:38:37+00:00

Clinical Trials

A worldwide quest is under way to find treatments to stop, slow or even prevent Alzheimer’s disease. Some of the most promising research is happening right here in San Diego. Many of the new drugs in development aim to modify the disease process by impacting the many brain changes that Alzheimer’s causes. In addition to investigating experimental drugs, many clinical trials include brain imaging studies and testing of blood or spinal fluid. Researchers hope these techniques will help diagnose Alzheimer’s disease in its earliest stages or even before symptoms appear.

We need your help. Without participation, finding a cure is virtually impossible.

Sign Up To Learn More About Trials

A groundbreaking local initiative that combines  San Diego’s resources in order to accelerate research and drug discovery projects to find a cure.

Click to download a PDF listing or scroll down below to see a current list of trials that are actively looking for participants.

Current Clinical Trials in San Diego

* Sharp Healthcare Clinical Research

  • ReCOGNITION Study: The purpose of this study is to see if the drug Piromelantine will improve slow wave sleep, improve memory and limit the effects of Alzheimer’s.
  • Navigate Study: The purpose of this study is to see if the drug LY3202626 slows the progression of Alzheimer’s.
  • Daybreak Study: The purpose of this study is to see if the drug LY3314814 slows the progression of Alzheimer’s.

For more information call 858-836-8350 or visit www.sharp.com/clinicaltrials.
* A valued partner who supports the mission, programs and services of Alzheimer’s San Diego.

*Pacific Research Network

  • Pacific Research Network (PRN) is a clinical research facility that specializes in examining new, investigational medications for the treatment of Alzheimer’s disease. With over 250 clinical research trials completed over the last 35 years, we are still looking for answers. If you or someone you know is interested in participating in a clinical research study or would like a no-cost memory exam, we are currently looking for volunteers for six Alzheimer’s disease trials.

For more information call 619-294-4302 or visit www.PRNSD.com.

* A valued partner who supports the mission, programs and services of Alzheimer’s San Diego.

Synergy Research Centers

  • Alzheimer’s and Agitation: A study for people with Alzheimer’s who have agitation. Participants can remain on current Alzheimer’s medication and will be given the study medication or placebo for treatment of agitation.
  • Mild-Moderate: A study for the treatment of mild to moderate Alzheimer’s disease.

For more information call 888-619-7272 or visit www.synergyresearchcenters.com.

Excell Research

  • Study for individuals with mild to moderate Alzheimer’s disease who have been on a stable dose of 10mg of Donepezil.
  • Study for individuals with Early Onset Alzheimer’s disease (or individuals suffering from memory problems but without a diagnosis of Alzheimer’s).
  • Study for individuals with mild cognitive impairment.
  • Study for adults with disruptive behavior due to Alzheimer’s (i.e. verbal outbursts, pacing, repetition, irritable).

For more information call 760-758-2222 or visit www.excellresearch.com.

The Research Center of Southern California

  • Daybreak Study: The purpose of this study is to see if the drug LY3314814 slows the progression of Alzheimer’s.

For more information call 760-732-0557 or visit www.neurocenter.com.

UC San Diego Shiley-Marcos Alzheimer’s Disease Research Center

  • A4: Anti-Amyloid in Asymptomatic AD: This trial will assess solanezumab (an antibody that helps the body rid the brain of beta amyloid) on persons with no symptoms of Alzheimer’s.
  • Cognitive Aging Longitudinal Study: The purpose of this study is to learn how the brain changes as we age. This is an observational study with no medication. It involves behavioral, medical and cognitive data collection and testing, as well as a neurologic exam. For individuals over the age of 65, with or without a diagnosis of dementia.
  • EMERGE – Biogen (BIIB037): This study will evaluate the efficacy and safety of Aducanumab (BIIB037) in persons with early Alzheimer’s disease. This drug is being evaluated to determine whether it can remove the amyloid plaques and slow the progression of symptoms in early Alzheimer’s.

For more information call 858-822-4800 or visit www.adrc.ucsd.edu.

UCSD Department of Psychiatry

  • Alzheimer’s Caregiver Study: This study investigates whether providing caregivers with coping tools will lower physiological markers related to heart disease. All study visits conducted in-home. For more information call 858-534-9479.
  • Mild Cognitive Impairment: This study compares the impact of a walking program, computer-based cognitive training and the combination of the two on memory, cognition and quality of life in adults with MCI. For more information call 858- 642-6375.
  • Mild Cognitive Impairment: The purpose of this study is to see if walking and/or computer cognitive training has a benefit on a person’s cognitive (mental) status. For more information call 858-642-6375.

For more information, please call us at 858-492-4400.
Learn more about clinical trials and research at:

Sign Up To Learn More About Trials